Clearmind Medicine Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on February 7, 2024, will not undergo review by the commission. The SEC's communication, dated February 14, 2024, was addressed to Dr. Adi Zuloff-Shani, the Chief Executive Officer of Clearmind Medicine. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. Clearmind Medicine was directed to Rules 460 and 461 should they wish to request acceleration of the registration process. The SEC provided contact information for further inquiries, directing them to Cindy Polynice.

Clearmind Medicine Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on February 7, 2024, will not undergo review by the commission. The SEC's communication, dated February 14, 2024, was addressed to Dr. Adi Zuloff-Shani, the Chief Executive Officer of Clearmind Medicine. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. Clearmind Medicine was directed to Rules 460 and 461 should they wish to request acceleration of the registration process. The SEC provided contact information for further inquiries, directing them to Cindy Polynice.